entertainment -WSS

entertainment

author：hotspot 2025-10-01 05:40:04 - browse：38

SAN DIEGO — One of the toughest subtypes of acute leukemia involves a genetic alteration in the KMT2A gene. Many cancers with this genetic alteration end up relapsing or don’t respond to treatment, but new data presented at the annual American Society of Hematology meeting offer hope of a new targeted therapy for these patients.

The study, called the Phase 2 Augment-101 trial, tested Syndax’s revumenib in patients with relapsed or refractory leukemia with these KMT2A genetic rearrangements. Overall, about 63% of the patients responded to the treatment, with many able to receive a potentially curative stem cell transplant later on, which is often the ultimate goal for patients with relapsed or refractory patients, said Ibrahim Aldoss, a hematologist-oncologist at City of Hope and the study’s presenter, in an interview.

“KMT2A-rearranged diseases represent 10% of all leukemia. They can be exceptionally hard to treat,” Aldoss said. “The median overall survival remains low with current available treatment. Right now there’s no targeted therapy for KMT2A-rearranged disease. We’re really excited about revumenib as it targets the mutation, and we’re seeing encouraging outcomes.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Will Ozempic

explore

WSS

STAT Readout Newsletter: Today's biggest biotech updates

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

STAT Summit: Michael J. Fox on progress in Parkinson's research

Beam Therapeutics to lay off 20% of its staff, re

FDA panel signals lack of confidence in Amgen cancer drug data

The explosion of genetic testing requires a new approach

Wikipedia

entertainment

hotspot

New air purifier tech could be key to improving indoor air quality

When women are denied an abortion, their children fare worse than peers

How one medical school became remarkably diverse

Why Charlie Gard's case is so disturbing to Americans

Psychedelics group wrestles with new pharma identity

Why health workers in Gaza are injured or die at high rates

United colonoscopy coverage change 'may cost lives,' doctors say

Why health workers in Gaza are injured or die at high rates

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Lawmakers consider Medicare pay reforms for doctors

hotspot

First Opinion Podcast: Long Covid needs a new approach

Analysis of telehealth claims data suggest service duplication

Impact of Dobbs ruling felt at reproductive medicine meeting

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

A Q&A with the global head of Boehringer Ingelheim's innovation unit

Stroke deaths set to near 10 million globally by 2050

focus

Wikipedia

explore

focus